Online Pharmacy US

Generalized anxiety disorder (GAD) is a prevalent and impairing disorder, associated with extensive psychiatric and medical comorbidity and usually characterized by a chronic course. Different drugs have been investigated in GAD; among them are the following: 1) SSRIS: paroxetine, sertraline, fluvoxamine and escitalopram; 2) SNRI1S: venlafaxine; 3) benzodiaze pines (BZS): alprazolam, diazepam and lorazepam; 4) azapirones (AZAS): buspirone; 5) (more…)

The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm. For discussing the problems related to the algorithm, we reviewed the reasons for the non-application of the algorithm and the reasons for dropout of patients (more…)

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. AZ-002 is an inhalation product candidate being developed for the acute treatment of panic attacks associated with panic disorder. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and (more…)

Unfortunately, we cannot answer this question as we found no guidelines or studies examining the cyclical use of alprazolam to treat premenstrual dysphoric disorder in patients concurrently taking quetiapine and a SSRI. This being the case coupl ed with not knowing the SSRI the patient is taking, plus the possibility of drug reactions occurring between SSRIs, an antipsychotic and a benzodiazepine, the NLH Q & A Service would recommend referring (more…)

New evidence; conclusions changed for:

CBT versus drug treatments Existing evidence re-evaluated, and reporting in benefits section further enhanced with additional detail. Existing categorisation changed. ‘CBT versus antidepressants (unclear which more effective, but weak evidence tha t effects of CBT may last longer than those of antidepressants)’ categorised as Unknown effectiveness.

CBT plus drug (more…)

AlexzaPharmaceuticals, Inc. ( Nasdaq: ALXA) announced today that it has initiateda Phase IIa clinical trial with AZ-002 (Staccato(TM) alprazolam) inpatients with panic disorder. AZ-002 is an inhalation product candidatebeing developed for the acute treatment of panic attacks associated withpanic disorder. The Phase IIa clinical trial is an in-clinic proof of concept study. [click link for full article] (Source: Mental Health News From Medical (more…)

This study investigated an anxiety-prone cognitive style (measured by the Anxious Thoughts and Tendencies Questionnaire, AT&T) as a predictor of the acute response to increasing alprazolam plasma levels in panic disorder. Panic disorder patients (n=26) were treated with escalating doses of alprazolam for 4 weeks, then a fixed dose of 1 mg four times a day for 4 weeks. At 0, 1, 2, 3, 4, 6, and 8 weeks, trough alprazolam plasma levels; clinical, (more…)

The objective of this study was to assess the effectiveness and efficacy of benzodiazepines in the treatment of GAD based on trial drop-out rates. We used a systematic review of randomized controlled trials that compared any of the thr ee best established benzodiazepines (diazepam, Lorazepam and aLprazolam) against placebo. Our primary outcome for effectiveness was withdrawal for any reason. Our secondary (more…)

All of us experience changes in our moods. Some days we might feel irritable and frustrated; othe r days, we’re happy and excited. However, individuals with bipolar disorder experience severe mood swings that impair their daily life and negatively affect their relationships.
Approximately 2.6 percent of American adults have bip olar disorder (formerly called manic depression and manic depressive disorder), according to the National Institute (more…)

AlexzaPharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiateda Phase IIa clinical trial with AZ-002 (Staccato(TM) alprazolam) inpatients with panic disorder. AZ-002 is an inhalation product candidatebeing developed for the acute treatment of panic attacks associated withpanic disorder. The Phase IIa clinical trial is an in-clinic proof of concept study. [click link for full article] (Source: Mental Health News From Medica (more…)